

Clinical study of neurodegenerative treatment for glaucoma by insulin intravitreal injection.

Abstract

Purpose: Our trial was to study the efficacy and safety of insulin intravitreal injection to treat neurodegeneration in glaucoma.

Method: Eleven subjects (11 eyes) enrolled in this trial; 10 patients received one injection intravitreal of insulin in a double masked randomized sham controlled. 5 patients received one injection of insulin and 5 patients received one injection of balanced salt solution (BSS) and was followed with Optical Coherence Tomography (OCT) and visual field (VF) with follow up of 168 days. the last patient received two injections of insulin within one month between each injection without masking the injection content, with a follow up of 877 days. All the patients have a correct ocular pressure and no ocular treatment was stopped.

Results: The five patients who received insulin intravitreal revealed a rapid improvement of DB, during the first month it remains stable. Therefore, the average improvement was 6.62 DB with follow up of 168 days. The 5 patients who received one injection of BSS showed no significant improvement they regain 1.45DB. The last patient who received two injections showed increase from 7.54DB to 17.22 DB with amelioration of the function with 9.68DB. No complication was observed during and after the treatment. In the OCT we noticed an improvement in the structure during the first month then returned to the initial values.

Conclusion: Insulin shows not only efficacy and safety but more than that, the visual field (VF) of the patients became stable and show no deterioration in all the follow up, which confirmed that insulin act to improve the function rather than structure. it means insulin reconnect the stoma and improve the neurite outgrowth This treatment will change the evolution of this pathology and protect the glaucomatous patients against blindness.

Key words: insulin – glaucoma – neurite outgrowth - retinal ganglion cells – visual field – average defect – nerve cells regeneration – insulin pathway.

Introduction

Glaucoma is a progressive degenerative disease (1) and the first leading cause of blindness, (1,2). In adult population the prevalence of primary open glaucoma (POAG) cases was estimated approximately 2% in patients over 40 and 10% in 80 years old patients, with a number of cases about 76 million in 2020 and could reach 111.8 million in 2040 (3), this increase in glaucomatous patients in the world will therefore more important given the increase in aging .the first risk factor of glaucoma is the ocular hypertonia, which is due to an increase in resistance to the flow of aqueous humor through the meshwork trabecula.

all the antiglaucoma drugs currently available are going to have an action on lowering eye pressure which decreases the risk and the rate of disease progression. but currently there is no serious treatment for the neurodegenerative problems.

Anatomically and developmentally, the eye is an extension of the brain. So, its share similar pathophysiological mechanisms as other degenerative disorders of the central nervous system (CNS) like the Alzheimer's disease (4).

In many studies the intra nasal insulin enhance the cognitive impairment in patients with AD.

Our approach is to use insulin in a clinical trial to treat neurodegeneration in glaucoma and solve this problem.

Materials and methods

1/ subjects:

- **Inclusion factors**

Patients selected for this study suffer of an open angle glaucoma with strain eyes balanced under medical treatment or

having previously under gone filtration surgery or laser SLT.

- **Exclusion factors**

Mono ophthalmic patients, diabetic retinopathy and high myopia, cataract, age related macular degeneration or another maculopathy, atrophic neuropathy from another origin, amblyopic eye.

2/Study design

This study was realized in an ophthalmology private clinical center located in Mostaganem, Algeria. In the confluence with the protocol of good clinical practice, this study and performed in adherence to the guide lines of the Helsinki declaration. informed consent was taking from patients.

Eleven patients (seven men and four women) with average age of 62 years (± 14), were recruited for this study, 10 patients are treated in a double masked sham controlled. 5 patients were received one injection of insulin rapid intravitreal 3 UI. The other 5 patients received 3 UI of balanced salt solution (BSS). with follow up of 168 days.

The last patient was a man aged 55 years old received two intravitreal injections of insulin 3UI within one month between each injection in a prospective study, with follow up of 877days.

In every visit a complete exam was applicated, enclosing the OTC, standard visual field examination, ocular tension and nerf optic retinopathy.

2/Evaluated parameters:

After ophthalmic examination (VA, SL; fundus of the eye) and control of ocular pressure by the Goldman applanation tonometer. all subjects were assessed with OCT Optovue exploration of RGC

(average thickness, focal lost vision, global lost vision, RNFL average thickness and visual field Rodenstock.

All the injections were conducted in the operating room after disinfection with the Betadine.

A ticket was placed to masque the reel continent of the injected substance.

the treatment of the last patient who received two injections was not masked.

Statistical analyses:

Statistical analyses were performed using XL-Stat/Excel software.

Result

Results of patients who received one injection

• **Statistical interpretation**

The function parameters are observed with the visual field (REODENSTOCK Field Analyzer device) by studying the indices average (dB, AD) and structural parameters using OCT (Optovue oct device) by studying the indices (RGC, RNFL).

Comparative study of the evolution of visual field in the treated group and the placebo group;

Average dB:

• **Insulin treatment**

The average dB of all patients treated was 13.17 dB before treatment and reached 19.79 dB at the 168 days of treatment, the average dB was showing an increase of 6.62 dB (Fig 1).




Figure 01 :The effect of insulin on dB in the treated groups during 168 days

• **Placebo treatment**

The placebo group showed a non-significant improvement in average dB, before treatment it was 20.17 dB while at the 168 day it attempts 21.62 dB, showing an increase of 1.45 dB (Fig 2).




Figure 02 :The effect of insulin on dB in placebo groups during 168 days

Average AD:

• **Insulin treatment**

The average AD of all patients treated was -5.396dB before treatment and reached -3.78dB at the day 168, showing an increase of 1.161dB (Fig 3).




Figure 03 :The effect of insulin on AD in treated groups during 168 days




Figure 05 : The effect of insulin on RGC in treated groups during 168 days

- **Placebo treatment**

The placebo group showed a non-significant improvement, it was -3.49 before treatment while at the 168 day it attempts -3.46 (Fig 4).




Figure 04: The effect of insulin on AD in placebo groups during 168 days

- **Placebo treatment**

The placebo group show a deterioration of 77.04 before treatment μm and 168 days after it was 75.72 μm (Fig 6).




Figure 06 : The effect of insulin on RGC in placebo groups during 168 days

[Comparative study of the evaluation of RGC and RNFL in the treated group and the placebo group:](#)

RGC:

- **Insulin treatment**

The average RGC of all patients treated was 76 μm before the treatment, it shows an increase until 20 days from the injection to attempt 90 μm and return after that to the initial value after 168 day (Fig 5).

RNFL:

- **Insulin treatment**

The average RNFL of all patients treated was 68.4 μm before treatment and it shows an increase until 80 μm on the 20 day and it return to the initial value after 168 day (Fig 7).




Figure 07 :The effect of insulin on RNFL in treated groups during 168 days.

- **Placebo treatment**

The placebo group was 74.7 μ m before treatment and decrease until 73.44 μ m 168 day after (**Fig 8**).




Figure08 : The effect of insulin on RNFL in placebo groups during 168 days

Results of the patient who received two injections.

The two graphs represent the evolution of decibel level over a period of 877days in the patient who received 2 injections rapid acting insulin with dose of 3UI.

The red area shows the points not seen by the patient in visual field and the blue area represent the points seen.

The Green sloping line going up from left to right across the two graphs shows amelioration and the yellow lines constitute the average decibel.

The first graph shows a field of vision on February 28,2020 before treatment.

The first and the second injection was realized on March 8,2020; March30,2020 respectively.

The second graph shows a field of vision on July22,2022. It shows an improvement of 9.58dB in average dB from 7.54 to 17.12dB. with decrease in the number of non-functional cells is visible in red and an increase in functional cells is shown in blue.




Figure09: Decibel level graphs presentation-dB level, with follow-up of 877days.

- **Red area:** the point not seen by the patient in visual field
- **Blue area:** the point seen by the patient in visual field
- **Green sloping line:** going up from left to right across the two graphs shows amelioration.
- **Yellow lines:** The average decibel

- The visual function field (VF) shows decibel (dB) examinations for left eye (**fig 10**).




Figure10: Visual Field changes after 2 injections of 3UI of rapid-acting insulin at one-month intervals with a follow-up of 877days (REODENSTOCK Field Analyzer device).

- (A) **Visual field before treatment**
- (B) **Visual field after first injection**
- (C) **Visual field after the second injection**

Statistical interpretation for the patient who received two injections

- Average dB (Insulin treatment with 2-injections)**




Figure 11: The effect of 2-injection with insulin on the dB levels in one patient during 877 days.

Average dB before treatment was 7.54 dB, one week after the first injection the average dB rise up to 13.76 dB One month after the second injection the dB attempt 21.07. After, the average dB shows a small drop but still remains high around 17 dB.

- Average AD (Insulin treatment)**




Figure 12: The effect of 2-injection with insulin on the AD levels in one patient during 877 days.

Average AD before treatment was -7.33 dB, one week after the first injection the average AD rise up to -6.06 dB. One month after the second injection the AD attempt to -3.44 dB. The average ameliorate from -7.33 to -4,51dB.

Discussion

Glaucoma and Alzheimer disease share many identical symptoms and characteristics as disease that affecting different locations of the brain (5-6) it has been mentioned as an Ocular Alzheimer's disease (7).

Glaucoma present with many common characteristics including increased cell death, abundant neurofibrillary tangles, consequent dystrophic neuritis, impaired deposits of APP (Amyloid protein precursor), which are resulting from many pathological pathways such as mTOR; Beta amyloid aggregation, Tau hyperphosphorylation and IDE (insulin degrading enzyme) downregulation, increased expression of apoptotic genes, disturbing energy metabolism and mitochondrial dysfunction with elevated OS (oxidative stress) causing DNA damage. (8).

Insulin is a potent neuroprotective agent that acts mainly against apoptosis, beta amyloid toxicity, oxidative stress, and other ischemia (9). On the other hand, the Insulin and IGF (Insulin-like growth factor) have essential roles in growth and development (10). It has been shown that antiapoptotic effects of insulin depends on the PI3K pathway to stimulate neurite formation (11).

Insulin is part of a family of peptides including insulin-like growth factors I/II (IGF-I/II) and relaxin (12). However, the expression of the insulin receptor is present in the retina (13,14)

The insulin Receptor and IGF-1R (Insulin-like growth factor-1 receptor) belong to a family of transmembrane receptor tyrosine kinases permit the kinase of the receptors to phosphorylate these proteins on tyrosine residues (15). Most of insulin responses are mediated by IRS-1 and IRS-2.

Insulin and its receptor are generally expressed throughout the brain and have been postulated to play a crucial role in synaptic plasticity. Although structural remodeling of dendritic spines is associated with stable expression of synaptic plasticity (12).

IR signaling plays an important role in neuronal proliferation during development, this was confirmed with a study that shown that IRS-2 mediated the effects of insulin on brain growth (17), outgrowth, maturation, and axons reconstruction (18). Moreover, insulin had an increasing effect on the protein expression of the dendritic scaffolding protein post-synaptic density-95 (PSD-95) in hippocampal CA1 region by PI3K/mTOR activation pathway. The process activates extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK) and PI3K/Akt (protein kinase B) pathways inhibiting GSK-3 β . These pathways are involved in inhibition of apoptosis, cell growth (and proliferation) and reduction in OS (19-20).

The insulin receptor tyrosine-kinase substrate P58/53 IRSp53 co-expressed with the IR in the synapse-rich molecular layer and in granule cell layer of the cerebellum, like-wise, in the cultured hippocampal neuron's synapses (21) The neurite formation depends on insulin and IGF2 presence which are important for NGF (nerve growth factor), there for this effect depend to the presence of the astrocytes.

Ser/Thr kinase Akt are important promote neuronal survival, Akt has been revealed as a primordial mediator of several aspects of neurite outgrowth, implicating elongation, branching and caliber. Moreover, activated Akt targets and inactivates pro-apoptotic proteins such as Bad, caspase 9, and glycogen synthase kinase 3 beta (GSK3 β). Activated Akt also

protects against neuronal hypoxia by NO-induced (nitric oxide) and stop apoptosis by preventing the transcriptional activity of p53 (22).

Vascular dysfunction of neurovascular contribute to the pathogenesis of glaucoma (23–24). This is sustained by a balance between the vasodilator action of NO and vasoconstrictor action of endothelin-1 (25–26), Which is regulate by insulin in vascular endothelium via PI3K and MAPK signaling (27). The PI3K dependent signaling cause an endothelial dysfunction by an imbalance between NO secretion and the hyperphosphorylation of caspase 9 cause endothelial cell apoptosis (28).

Insulin has antiapoptotic effects by mTOR activation which suggesting that p70SK protein (one of the downstream targets of PI3K/Akt/mTOR pathway, may be one of the mechanisms through which insulin prevent apoptosis (29).

This activation modulates mitochondrial electron transport chain function, and inhibits also FOXO1/HMOX1 and conserves the NAD⁺/NADH ratio, which regulates the SIRT1/PGC1 α pathway for mitochondrial biogenesis and function (30).

All of this show that enhancing mitochondrial function may be an important therapeutic benefit to targeting insulin signaling in glaucoma pathogenesis.

The high levels of insulin in brain extracts, was consolidated by the detection of insulin secretion in neuronal cultures (31), and the presence of insulin immunoreaction inside the Golgi and the rough endoplasmic reticulum in the brain (32). Which was detected using insulin antisera, in the retinal layers including the ganglion cell layer, and this was approved

in human and mouse retina, as well as optic nerve glial cells (33).

There is evidence that the insulin had a central origin, firstly, C-peptide was found in the brain from human cadavers, and the highest content were specifically in the hypothalamus (34). Secondly, the synaptic vesicles within nerve-endings store the insulin in the adult rat's brain (35).

Furthermore, insulin mRNA was located in the CA1 and CA3 regions of the hippocampus, precisely in the dentate gyrus, and in the granule cell layer of the olfactory bulbs of the neonatal rabbit brain (36).

Usually, insulin protect against beta amyloid; in the case of Insulin resistance which is closely associated with reduced responses to insulin signaling in IR, IRS-1, PI3K and IGF1 in IGF1R, IRS-2, PI3K signaling pathways, the A β (Beta amyloid) metabolism is affected as a consequence of Tau hyper phosphorylation (37), that has been implicated in neurofibrillary end threads and tangles (NFT) formation in both AD (Alzheimer disease) and glaucoma (38).

Glucose hypometabolism results in both reduced glucose transporter expression and the decreased O-GlcNAcylation of tau. They proposed that hypometabolism in the brain reduces the O-GlcNAcylation of tau that conversely increases its phosphorylation, which induces the NFTs (neurofibrillary tangle) (39-40).

Accordingly, impaired cerebral glucose metabolism, mainly thiamine metabolism and insulin resistance, could promote A β accumulation and tau hyper phosphorylation.

The reduced brain insulin/PI3K/Akt pathway leads to the overactivation of

GSK-3 β calpain-1 and downregulation of O-GlcNAcylation, which promoted altered tau hyperphosphorylation and neurodegeneration (41).

By contrast, serine phosphorylation of IRS-1/2 by C-Jun N-terminal Kinase

(JNK1) and other kinases down regulates insulin-stimulated tyrosine phosphorylation, and that corresponds with insulin resistance (42). Likewise, ubiquitin-mediated degradation of IRS-1/2 also aid to insulin resistance formation (43) (fig 13).




Figure 13 : Insulin pathways signaling

On the other hand, the presence of the GLUT was noticed in the brain likewise: GLUT-1; GLUT-2; GLUT-3 and GLUT-4; with different level and distribution than the peripheral (Table).

Table 1: the different distribution of Glut-transporters between the central and peripheral region

Glucose transport Isoforms	location	abundance in central	abundance in periphery
GLUT-1	ubiquitous	+++	+
GLUT-2	hypothalamus	++	+++
GLUT-3	cerebellum, striatum , cortex,hippocampus	+++	+
GLUT-4	olfactory bulb , hyppocampus (dentate gyrus) And hypothalamus cerebellum	+	+++
GLUT-8	hypothalamus, dentate gyrus , amygdala And primary olfactory cortex	++	-

The inflammatory responses are closely associated with the development of insulin resistance in peripheral and central tissues and the presence of TNF α producing hypothalamic inflammation (44). This inflammation interacts with the processing

and deposit of β - amyloid peptide ($A\beta$), with low amount of insulin producing anti-inflammatory effect. JNK inhibitors stimulate the neuroinflammatory response, while JNK activation promotes neuroinflammation and facilitates insulin resistance (45) (fig14).




Figure 14: relationship between alterations of insulin signaling and glaucoma disease pathogenesis.

Conclusion

In this trial we investigated the insulin effects to promote the visual function; this regeneration is visible on visual field. as we saw in discussion how the insulin promotes the neurite out growth, but also the increase in visual function remains substantially during this study (877 days) the use of tow injections shows better results. These results are confirmed returning to different theoretical and experimental studies that we have mentioned it in the discussion. It explains

that insulin promote the regeneration of synaptic and dendrites, by activating the different insulin signaling pathways.

Other studies will be carried out for the generalization of this treatment in all glaucomatous patients.

this treatment will change the dramatic evolution of this pathology, we hope that no patient will reach the stage of blindness, other studies are in progress for better evolution of this new treatment.

Références :

- 1 – J Aliancy, WD Stamer, B. Wirostko A, Review of nitric oxide for the treatment of glaucomatous Disease *ophthalmol ther*, 6 (2) (2017), pp. 221-232.
- 2 – J Song, P-F Deng, SS Stinnett, DL Epstein, PV. Rao effects of cholesterol-lowering stations on the aqueous humor outflow pathway invest *ophthalmol Vis Sci*, 46 (7) (2005), pp. 2424-2432.
- 3 – D. Blumberg, A. Skatt, J.M. Liebmann, Chaopter 5 emerging risk factors for glaucoma onset and progression *Prong Brain Res*, 221 (2015), pp. 81-101.
- 4 – Noel C.Y.ChanMBChB, FRCSEd, Jane W.ChanMD, Glaucoma as a neurodegenerative disease : a clinician perspective ; *Advances in ophthalmology and optometry*, Volume 6, august 2021, Pages 263-274.
- 5 - Johnston H, Boutin H, Allan SM. Assessing the contribution of inflammation in models of Alzheimer’s disease. *Biochem Soc Trans* (2011) 39(4):886–90. doi:10.1042/BST0390886
- 6 - Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A. Neuroinflammation in Alzheimer’s disease and Parkinson’s disease: are microglia pathogenic in either disorder? *Int Rev Neurobiol* (2007) 82:235–46. doi:10.1016/S0074-7742(07)82012-5.
- 7 - Pistell PJ, Morrison CD, Gupta S, Knight AG, Keller JN, Ingram DK, et al. Cognitive impairment following high fat diet consumption is associated with brain inflammation. *J Neuroimmunol* (2010) 219(1–2):25–32. doi:10.1016/j.jneuroim.2009.11.010
- 8 - Muneeb A. Faiq, Rima Dada, Daman Saluja, Tanuj Dada. Glaucoma – Diabetes of the brain: A radical hypothesis about its nature and pathogenesis. Laboratory for Molecular Reproduction and Genetics, Department of Anatomy, All India Institute of Medical Sciences, New Delhi 110029, India c Medical Biotechnology Laboratory, Dr. B.R. Ambedkar Centre for Biomedical Research, University of Delhi, Delhi 110007, India (2014) <http://dx.doi.org/10.1016/j.mehy.2014.02.005>
- 9 - Santos MS, Pereira EM, Carvaho AP. Stimulation of immunoreactive insulin release by glucose in rat brain synaptosomes. *Neurochem Res* (1999) 24(1):33–6. doi:10.1023/A:1020971812098
- 10 - Dupont and LeRoith , 2001;55(suppl 2):22–26 , *Clinical Endocrinology Branch, NIDDK, Bethesda, Md., USA.*
- 11 - Leopold P. Neuronal differentiation: TOR and insulin receptor pathways set the tempo. *Cell* (2004) 119(1):4–5. doi:10.1016/j.cell.2004.09.024.
- 12 - Weiss, M.; Steiner, D.F.; Philipson, L.H. *Insulin Biosynthesis, Secretion, Structure, and Structure-Activity Relationships*; Endotext, K.R., Ed.; MDTtext.com, Inc.: South Dartmouth, MA, USA, 2000.
- 13 - Havrankova, J.; Roth, J.; Brownstein, M.J. Insulin receptors are widely distributed in the central nervous system of the rat. *Nature* 1978, 272, 827–829. [CrossRef] [PubMed].
- 14 - Plum, L.; Schubert, M.; Brüning, J.C. The role of insulin receptor signaling in the brain. *Trends Endocrinol. Metab.* 2005, 16, 59–65. [CrossRef] [PubMed].

- 15 – J. M. Bateman a, H. McNeill. Visions & Reflections Insulin/IGF signalling in neurogenesis. The Wolfson Centre For Age-Related Disease, Hodgkin Building, King's College London, Guy's Campus, London, SE1 1UL (United Kingdom), Samuel Lunenfeld Research Institute, 600 University Avenue, Room 884, Toronto, Ontario M5G 1X5 (Canada) : DOI 10.1007/s00018-006-6036-4
- 16 – Insulin promotes dendritic spine and synapse formation by the PI3K/Akt/Mtor and Rac1 signaling pathways ; Author links open overlay panel Cheng-Che Lee Chiungè Chun Huang Kuei Sen Hsu. *Neuropharmacology* Volume 61, Issue 4, September 2011, Pages 567-879. <https://doi.org/10.1016/j.neuropharm.2011.06.003>
- 17 - Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. *J Neurosci* (2003) 23(18):7084–92.
- 18 - Xu QG, Li XQ, Kotecha SA, Cheng C, Sun HS, Zochodne DW. Insulin as an in vivo growth factor. *Exp Neurol* (2004) 188(1):43–51. doi:10.1016/j.expneurol.2004.03.008.
- 19 - Evans RM, Hui S, Perkins A, Lahiri DK, Poirier J, Farlow MR. Cholesterol and APOE genotype interact to influence Alzheimer disease progression. *Neurology* (2004) 62(10):1869–71. doi:10.1212/01.WNL.0000125323.15458.3 F
- 20 - Frodin M, Gammeltoft S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. *Mol Cell Endocrinol* (1999) 151(1–2):65–77. doi:10.1016/S0303-7207(99)00061-1.
- 21 - Abbott MA, Wells DG, Fallon JR. The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses. *J Neurosci* (1999) 19(17):7300–8.
- 22 - Yamaguchi, A.; Tamatani, M.; Matsuzaki, H.; Namikawa, K.; Kiyama, H.; Vitek, M.P.; Mitsuda, N.; Tohyama, M. Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53. *J. Biol. Chem.* 2001, 276, 5256–5264. [CrossRef]
- 23 - Dienstbier, E.; Balik, J.; Kafka, H. A contribution to the theory of the vascular origin of glaucoma. *Br. J. Ophthalmol.* 1950, 34, 47–58. [CrossRef] [PubMed]
- 24 - Wareham, K.L.; Calkins, D.J. The Neurovascular Unit in Glaucomatous Neurodegeneration. *Front Cell Dev. Biol.* 2020, 8, 452. [CrossRef] [PubMed]
- 25 - Tziomalos, K.; Athyros, V.G.; Karagiannis, A.; Mikhailidis, D.P. Endothelial dysfunction in metabolic syndrome: Prevalence, pathogenesis and management. *Nutr. Metab. Cardiovasc. Dis.* 2010, 20, 140–146. [CrossRef] [PubMed]
- 26 - Roddy, G.W. Metabolic Syndrome Is Associated with Ocular Hypertension and Glaucoma. *J. Glaucoma* 2020, 29, 726–731. [CrossRef]
- 27 - Muniyappa, R.; Sowers, J.R. Role of insulin resistance in endothelial dysfunction. *Rev. Endocr. Metab. Disord.* 2013, 14, 5–12. [CrossRef]
- 28 - Kim, A.J.; Montagnani, M.; Koh, K.K.; Quon, M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction : Molecular and pathophysiological mechanisms. *Circulation* 2006, 113, 1888–1904. [CrossRef]

- 29 - Ryu BR, Ko HW, Jou I, Noh JS, Gwag BJ. Phosphatidylinositol 3-kinasemediated regulation of neuronal apoptosis and necrosis by insulin and IGF-I. *J Neurobiol* (1999) 39(4):536–46. doi:10.1002/(SICI)1097-4695(19990615)39
- 30 - Cheng, Z.; Tseng, Y.; White, M.F. Insulin signaling meets mitochondria in metabolism. *Trends Endocrinol. Metab.* 2010, 21, 589–598. [CrossRef]
- 31 - Devaskar, S.U.; Giddings, S.J.; Rajakumar, P.A.; Carnaghi, L.R.; Menon, R.K.; Zahm, D.S. Insulin gene expression and insulin synthesis in mammalian neuronal cells. *J. Biol. Chem.* 1994, 269, 8445–8454. [CrossRef]
- 32 - Schechter, R.; Beju, D.; Gaffney, T.; Schaefer, F.; Whetsell, L. Preproinsulin I and II mRNAs and insulin electron microscopic immunoreaction are present within the rat fetal nervous system. *Brain Res.* 1996, 736, 16–27. [CrossRef]
- 33 - Das, A.; Pansky, B.; Budd, G.C.; Kollarits, C.R. Immunocytochemistry of mouse and human retina with antisera to insulin and S-100 protein. *Curr. Eye Res.* 1984, 3, 1397–1403. [CrossRef] [PubMed]
- 34 - Wei LT, Matsumoto H, Rhoads DE. Release of immunoreactive insulin from rat brain synaptosomes under depolarizing conditions. *J Neurochem* (1990) 54(5):1661–5. doi:10.1111/j.1471-4159.1990.tb01219.x
- 35 - Kar S, Chabot JG, Quirion R. Quantitative autoradiographic localization of [125I]insulin-like growth factor I, [125I]insulin-like growth factor II, and [125I]insulin receptor binding sites in developing and adult rat brain. *J Comp Neurol* (1993) 333(3):375–97. doi:10.1002/cne.903330306
- 36 - Baura GD, Foster DM, Porte D Jr, Kahn SE, Bergman RN, Cobelli C, et al. Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. *J Clin Invest* (1993) 92(4):1824–30. doi:10.1172/JCI116773
- 37 - Rensink AA, Otte-Holler I, de Boer R, Bosch RR, ten Donkelaar HJ, de Waal RM, et al. Insulin inhibits amyloid beta-induced cell death in cultured human brain pericytes. *Neurobiol Aging* (2004) 25(1):93–103. doi:10.1016/S0197-4580(03) 00039-3
- 38 - Reddy PH, Manczak M, Mao P, Calkins MJ, Reddy AP, Shirendeb U. Amyloid- β and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline. *J Alzheimers Dis* 2010;20: 499–512.
- 39 - Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. *Ann Neurol* (1994) 35(5):546–51. doi:10.1002/ana. 410350507
- 40 - Liu F, Shi J, Tanimukai H, Gu J, Grundke-Iqbal I, Iqbal K, et al. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. *Brain* (2009) 132(Pt 7):1820–32. doi:10.1093/brain/awp099
- 41 - Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Brain glucose transporters, OGlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. *J Neurochem* (2009) 111(1):242–9. doi:10.1111/j.1471-4159.2009.06320.x
- 42 - Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin

receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. *J Biol Chem* (2002) 277(2):1531–7. doi:10.1074/jbc.M101521200

43 - Krebs DL, Hilton DJ. A new role for SOCS in insulin action. Suppressor of cytokine signaling. *Sci STKE* (2003) 2003(169):e6. doi:10.1126/stke.2003.169.pe6

44 - Tu YF, Tsai YS, Wang LW, Wu HC, Huang CC, Ho CJ. Overweight worsens apoptosis, neuroinflammation and blood-brain barrier damage after hypoxic ischemia in neonatal brain through JNK hyperactivation. *J Neuroinflammation* (2011) 8:40. doi:10.1186/1742-2094-8-40

UNDER PEER REVIEW